(VIANEWS) – ORANGE (ORA.PA), TIETOEVRY (TIETO.OL), CROSSWOOD (CROS.PA) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio at the moment. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. ORANGE (ORA.PA)
95.89% Payout Ratio
Orange S.A. provides various fixed telephony and mobile telecommunications, data transmission, and other value-added services to customers, businesses, and other telecommunications operators in France and internationally. The company operates through France; Spain and Other European Countries; The Africa and Middle East; Enterprise; International Carriers & Shared Services; and Mobile Financial Services segments. It offers mobile services, such as voice, SMS, and data; fixed broadband and narrowband services, as well as fixed network business solutions, including voice and data; and convergence packages. The company also sells mobile handsets, broadband equipment, connected devices, and accessories. In addition, it provides IT and integration services comprising unified communication and collaboration services, such as LAN and telephony, consultancy, integration, and project management; hosting and infrastructure services, including cloud computing; customer relations management and other applications services; security services; and video conferencing, as well as sells related equipment. Further, the company offers national and international roaming services; online advertising services; and mobile virtual network operators, network sharing, and mobile financial services, as well as sells equipment to external distributors and brokers. It markets its products and services under the Orange brand. The company was formerly known as France Telecom and changed its name to Orange S.A. in July 2013. Orange S.A. is headquartered in Issy-les-Moulineaux, France.
Earnings Per Share
As for profitability, ORANGE has a trailing twelve months EPS of €0.73.
PE Ratio
ORANGE has a trailing twelve months price to earnings ratio of 15.68. Meaning, the purchaser of the share is investing €15.68 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.44%.
Sales Growth
ORANGE’s sales growth is 1.7% for the present quarter and 2.5% for the next.
More news about ORANGE.
2. TIETOEVRY (TIETO.OL)
81.87% Payout Ratio
TietoEVRY Oyj operates as a software and services company. It operates through six segments: Tietoevry Create, Tietoevry Banking, Tietoevry Care, Tietoevry Industry, Tietoevry Transform, and Tietoevry Connect. The Tietoevry Create segment provides digital agenda to create competitive products, as well as uses design, data, and cloud technologies for data-driven businesses. This segment also offers software and data engineering services. The Tietoevry Banking segment provides software products for digital transformation and financial institutions. The Tietoevry Care segment offers modular and interoperable software, reinventing Nordic health, and social care services. The Tietoevry Industry segment offers software and data solutions across various industries, such as public sector, pulp and paper, and utilities. The Tietoevry Transform segment provides enterprise-wide transformation across customers' business processes, applications and infrastructure. The Tietoevry Connect segment operates a cloud platform that provides a range of infrastructure choices ensuring security, resilience, and compliance for the customer's business. The company was formerly known as Tieto Oyj and changed its name to TietoEVRY Oyj in December 2019. TietoEVRY Oyj was founded in 1968 and is headquartered in Espoo, Finland.
Earnings Per Share
As for profitability, TIETOEVRY has a trailing twelve months EPS of kr18.29.
PE Ratio
TIETOEVRY has a trailing twelve months price to earnings ratio of 18.64. Meaning, the purchaser of the share is investing kr18.64 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.07%.
More news about TIETOEVRY.
3. CROSSWOOD (CROS.PA)
51.06% Payout Ratio
Crosswood SA engages in real estate activity in France. Its property portfolio includes shops and offices, and housing properties. The company was formerly known as Desquenne et Giral. Crosswood SA was incorporated in 1935 and is based in Paris, France. Crosswood SA operates as a subsidiary of Compagnie Financiere De Broceliande.
Earnings Per Share
As for profitability, CROSSWOOD has a trailing twelve months EPS of €1.1.
PE Ratio
CROSSWOOD has a trailing twelve months price to earnings ratio of 15.45. Meaning, the purchaser of the share is investing €15.45 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.48%.
Volume
Today’s last reported volume for CROSSWOOD is 31 which is 90.71% below its average volume of 334.
Yearly Top and Bottom Value
CROSSWOOD’s stock is valued at €17.00 at 22:10 EST, under its 52-week high of €17.50 and way above its 52-week low of €4.58.
Moving Average
CROSSWOOD’s value is way higher than its 50-day moving average of €8.67 and way higher than its 200-day moving average of €8.04.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Mar 6, 2023, the estimated forward annual dividend rate is 0.11 and the estimated forward annual dividend yield is 0.74%.
More news about CROSSWOOD.
4. TUBIZE-FIN (TUB.BR)
39.2% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.94.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 40.46. Meaning, the purchaser of the share is investing €40.46 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.88%.
Volume
Today’s last reported volume for TUBIZE-FIN is 1517 which is 78.87% below its average volume of 7182.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.1%.
More news about TUBIZE-FIN.
